Enzo Biochem, Inc. (NYSE: ENZ) Stock Competitors & Peer Comparison
See ENZ's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ENZ and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ENZ | $0.31 | -6.08% | 16.4M | -2.24 | -$0.14 | +31.87% |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.69% |
| TMO | $647.89 | +5.67% | 238.4B | 27.70 | $23.16 | +0.29% |
| DHR | $209.36 | +3.01% | 147.1B | 26.23 | $7.98 | +0.69% |
| NTRA | $349.44 | +2.24% | 50.2B | -265.74 | -$1.32 | N/A |
| IQV | $270.94 | +1.98% | 44.4B | 22.22 | $12.13 | N/A |
| A | $153.58 | +4.62% | 42.4B | 25.85 | $5.81 | +0.67% |
| IDXX | $519.83 | +2.02% | 40.3B | 35.92 | $14.22 | N/A |
| ILMN | $228.00 | +9.51% | 33.6B | 44.19 | $5.03 | N/A |
| WAT | $420.59 | +2.58% | 31.2B | 30.49 | $13.68 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
ENZ vs DHR-PB Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, ENZ's ROE is -0.39%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, ENZ is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
ENZ vs TMO Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, TMO has a market cap of 238.4B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while TMO trades at $647.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas TMO's P/E ratio is 27.70. In terms of profitability, ENZ's ROE is -0.39%, compared to TMO's ROE of +0.13%. Regarding short-term risk, ENZ is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
ENZ vs DHR Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, DHR has a market cap of 147.1B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while DHR trades at $209.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas DHR's P/E ratio is 26.23. In terms of profitability, ENZ's ROE is -0.39%, compared to DHR's ROE of +0.08%. Regarding short-term risk, ENZ is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
ENZ vs NTRA Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, NTRA has a market cap of 50.2B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while NTRA trades at $349.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas NTRA's P/E ratio is -265.74. In terms of profitability, ENZ's ROE is -0.39%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, ENZ is more volatile compared to NTRA. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check NTRA's competition here
IQVIA Holdings Inc. (NYSE: IQV)
ENZ vs IQV Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, IQV has a market cap of 44.4B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while IQV trades at $270.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas IQV's P/E ratio is 22.22. In terms of profitability, ENZ's ROE is -0.39%, compared to IQV's ROE of +0.22%. Regarding short-term risk, ENZ is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check IQV's competition here
Agilent Technologies, Inc. (NYSE: A)
ENZ vs A Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, A has a market cap of 42.4B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while A trades at $153.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas A's P/E ratio is 25.85. In terms of profitability, ENZ's ROE is -0.39%, compared to A's ROE of +0.20%. Regarding short-term risk, ENZ is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check A's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
ENZ vs IDXX Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, IDXX has a market cap of 40.3B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while IDXX trades at $519.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas IDXX's P/E ratio is 35.92. In terms of profitability, ENZ's ROE is -0.39%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, ENZ is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check IDXX's competition here
Illumina, Inc. (NASDAQ: ILMN)
ENZ vs ILMN Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, ILMN has a market cap of 33.6B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while ILMN trades at $228.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas ILMN's P/E ratio is 44.19. In terms of profitability, ENZ's ROE is -0.39%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, ENZ is more volatile compared to ILMN. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check ILMN's competition here
Waters Corporation (NYSE: WAT)
ENZ vs WAT Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, WAT has a market cap of 31.2B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while WAT trades at $420.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas WAT's P/E ratio is 30.49. In terms of profitability, ENZ's ROE is -0.39%, compared to WAT's ROE of +0.02%. Regarding short-term risk, ENZ is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check WAT's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
ENZ vs DGX Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, DGX has a market cap of 27.3B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while DGX trades at $246.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas DGX's P/E ratio is 24.39. In terms of profitability, ENZ's ROE is -0.39%, compared to DGX's ROE of +0.14%. Regarding short-term risk, ENZ is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check DGX's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
ENZ vs MTD Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, MTD has a market cap of 26.9B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while MTD trades at $1,376.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas MTD's P/E ratio is 30.58. In terms of profitability, ENZ's ROE is -0.39%, compared to MTD's ROE of -12.00%. Regarding short-term risk, ENZ is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check MTD's competition here
Labcorp Holdings Inc. (NYSE: LH)
ENZ vs LH Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, LH has a market cap of 25.9B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while LH trades at $324.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas LH's P/E ratio is 18.72. In terms of profitability, ENZ's ROE is -0.39%, compared to LH's ROE of +0.12%. Regarding short-term risk, ENZ is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
ENZ vs GH Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, GH has a market cap of 23.6B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while GH trades at $176.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas GH's P/E ratio is -50.33. In terms of profitability, ENZ's ROE is -0.39%, compared to GH's ROE of +2.11%. Regarding short-term risk, ENZ is more volatile compared to GH. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
ENZ vs EXAS Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas EXAS's P/E ratio is -95.37. In terms of profitability, ENZ's ROE is -0.39%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, ENZ is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
ENZ vs MEDP Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, MEDP has a market cap of 17.3B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while MEDP trades at $618.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas MEDP's P/E ratio is 36.37. In terms of profitability, ENZ's ROE is -0.39%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, ENZ is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check MEDP's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
ENZ vs ILMNV Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas ILMNV's P/E ratio is N/A. In terms of profitability, ENZ's ROE is -0.39%, compared to ILMNV's ROE of N/A. Regarding short-term risk, ENZ is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check ILMNV's competition here
Revvity, Inc. (NYSE: RVTY)
ENZ vs RVTY Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, RVTY has a market cap of 15.6B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while RVTY trades at $145.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas RVTY's P/E ratio is 26.19. In terms of profitability, ENZ's ROE is -0.39%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, ENZ is more volatile compared to RVTY. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check RVTY's competition here
PerkinElmer, Inc. (NYSE: PKI)
ENZ vs PKI Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas PKI's P/E ratio is 41.45. In terms of profitability, ENZ's ROE is -0.39%, compared to PKI's ROE of +0.03%. Regarding short-term risk, ENZ is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check PKI's competition here
ICON Public Limited Company (NASDAQ: ICLR)
ENZ vs ICLR Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, ICLR has a market cap of 13.2B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while ICLR trades at $174.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas ICLR's P/E ratio is 14.07. In terms of profitability, ENZ's ROE is -0.39%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, ENZ is more volatile compared to ICLR. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check ICLR's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
ENZ vs CRL Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, CRL has a market cap of 13.1B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while CRL trades at $279.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas CRL's P/E ratio is 27.53. In terms of profitability, ENZ's ROE is -0.39%, compared to CRL's ROE of -0.08%. Regarding short-term risk, ENZ is more volatile compared to CRL. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check CRL's competition here
Qiagen N.V. (NYSE: QGEN)
ENZ vs QGEN Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, QGEN has a market cap of 8.8B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while QGEN trades at $43.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas QGEN's P/E ratio is 17.55. In terms of profitability, ENZ's ROE is -0.39%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, ENZ is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check QGEN's competition here
RadNet, Inc. (NASDAQ: RDNT)
ENZ vs RDNT Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, RDNT has a market cap of 6.1B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while RDNT trades at $77.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas RDNT's P/E ratio is 167.65. In terms of profitability, ENZ's ROE is -0.39%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, ENZ is more volatile compared to RDNT. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check RDNT's competition here
Sotera Health Company (NASDAQ: SHC)
ENZ vs SHC Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, SHC has a market cap of 5.4B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while SHC trades at $19.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas SHC's P/E ratio is 19.77. In terms of profitability, ENZ's ROE is -0.39%, compared to SHC's ROE of +0.27%. Regarding short-term risk, ENZ is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check SHC's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
ENZ vs BLLN Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, BLLN has a market cap of 4.8B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while BLLN trades at $105.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas BLLN's P/E ratio is 148.96. In terms of profitability, ENZ's ROE is -0.39%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, ENZ is more volatile compared to BLLN. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check BLLN's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
ENZ vs SYNH Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas SYNH's P/E ratio is 61.40. In terms of profitability, ENZ's ROE is -0.39%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, ENZ is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check SYNH's competition here
GRAIL Inc. (NASDAQ: GRAL)
ENZ vs GRAL Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, GRAL has a market cap of 3.3B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while GRAL trades at $76.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas GRAL's P/E ratio is -7.78. In terms of profitability, ENZ's ROE is -0.39%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, ENZ is more volatile compared to GRAL. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check GRAL's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
ENZ vs OLK Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas OLK's P/E ratio is -96.59. In terms of profitability, ENZ's ROE is -0.39%, compared to OLK's ROE of -0.07%. Regarding short-term risk, ENZ is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check OLK's competition here
Veracyte, Inc. (NASDAQ: VCYT)
ENZ vs VCYT Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, VCYT has a market cap of 3.2B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while VCYT trades at $40.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas VCYT's P/E ratio is 20.07. In terms of profitability, ENZ's ROE is -0.39%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, ENZ is more volatile compared to VCYT. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check VCYT's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
ENZ vs WGS Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, WGS has a market cap of 2.8B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while WGS trades at $98.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas WGS's P/E ratio is 262.89. In terms of profitability, ENZ's ROE is -0.39%, compared to WGS's ROE of -0.39%. Regarding short-term risk, ENZ is more volatile compared to WGS. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check WGS's competition here
CareDx, Inc (NASDAQ: CDNA)
ENZ vs CDNA Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, CDNA has a market cap of 2.7B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while CDNA trades at $54.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas CDNA's P/E ratio is 62.67. In terms of profitability, ENZ's ROE is -0.39%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, ENZ is more volatile compared to CDNA. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check CDNA's competition here
Personalis, Inc. (NASDAQ: PSNL)
ENZ vs PSNL Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while PSNL trades at $16.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas PSNL's P/E ratio is -14.77. In terms of profitability, ENZ's ROE is -0.39%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, ENZ is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
ENZ vs OPK Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while OPK trades at $1.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas OPK's P/E ratio is -5.81. In terms of profitability, ENZ's ROE is -0.39%, compared to OPK's ROE of -0.06%. Regarding short-term risk, ENZ is more volatile compared to OPK. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
ENZ vs CSTL Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, CSTL has a market cap of 1.1B. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while CSTL trades at $35.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas CSTL's P/E ratio is -53.79. In terms of profitability, ENZ's ROE is -0.39%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, ENZ is more volatile compared to CSTL. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
ENZ vs FLGT Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, FLGT has a market cap of 604.4M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while FLGT trades at $21.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas FLGT's P/E ratio is 2128.00. In terms of profitability, ENZ's ROE is -0.39%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, ENZ is more volatile compared to FLGT. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
ENZ vs GRALV Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas GRALV's P/E ratio is N/A. In terms of profitability, ENZ's ROE is -0.39%, compared to GRALV's ROE of N/A. Regarding short-term risk, ENZ is more volatile compared to GRALV. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check GRALV's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
ENZ vs NEO Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, NEO has a market cap of 485.4M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while NEO trades at $19.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas NEO's P/E ratio is 145.31. In terms of profitability, ENZ's ROE is -0.39%, compared to NEO's ROE of -0.06%. Regarding short-term risk, ENZ is more volatile compared to NEO. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check NEO's competition here
Global Cord Blood Corporation (NYSE: CO)
ENZ vs CO Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas CO's P/E ratio is 5.06. In terms of profitability, ENZ's ROE is -0.39%, compared to CO's ROE of +0.11%. Regarding short-term risk, ENZ is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for ENZ.Check CO's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
ENZ vs MYGN Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, MYGN has a market cap of 366.5M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while MYGN trades at $4.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas MYGN's P/E ratio is -29.85. In terms of profitability, ENZ's ROE is -0.39%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, ENZ is more volatile compared to MYGN. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check MYGN's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
ENZ vs FLDM Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas FLDM's P/E ratio is -4.74. In terms of profitability, ENZ's ROE is -0.39%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, ENZ is more volatile compared to FLDM. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check FLDM's competition here
Prenetics Global Limited (NASDAQ: PRENW)
ENZ vs PRENW Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, PRENW has a market cap of 277.8M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while PRENW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas PRENW's P/E ratio is N/A. In terms of profitability, ENZ's ROE is -0.39%, compared to PRENW's ROE of -0.49%. Regarding short-term risk, ENZ is more volatile compared to PRENW. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check PRENW's competition here
Biodesix, Inc. (NASDAQ: BDSX)
ENZ vs BDSX Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, BDSX has a market cap of 225.5M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while BDSX trades at $28.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas BDSX's P/E ratio is -8.74. In terms of profitability, ENZ's ROE is -0.39%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, ENZ is more volatile compared to BDSX. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
ENZ vs XGN Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, XGN has a market cap of 181M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while XGN trades at $7.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas XGN's P/E ratio is -9.25. In terms of profitability, ENZ's ROE is -0.39%, compared to XGN's ROE of -1.22%. Regarding short-term risk, ENZ is more volatile compared to XGN. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check XGN's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
ENZ vs IMDX Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, IMDX has a market cap of 129.8M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while IMDX trades at $3.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas IMDX's P/E ratio is -2.70. In terms of profitability, ENZ's ROE is -0.39%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, ENZ is more volatile compared to IMDX. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check IMDX's competition here
Genetron Holdings Limited (NASDAQ: GTH)
ENZ vs GTH Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas GTH's P/E ratio is -1.11. In terms of profitability, ENZ's ROE is -0.39%, compared to GTH's ROE of -1.01%. Regarding short-term risk, ENZ is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
ENZ vs GENE Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas GENE's P/E ratio is -38.25. In terms of profitability, ENZ's ROE is -0.39%, compared to GENE's ROE of -1.85%. Regarding short-term risk, ENZ is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check GENE's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
ENZ vs SERA Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, SERA has a market cap of 76M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while SERA trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas SERA's P/E ratio is -3.06. In terms of profitability, ENZ's ROE is -0.39%, compared to SERA's ROE of -0.47%. Regarding short-term risk, ENZ is more volatile compared to SERA. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
ENZ vs PRPO Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, PRPO has a market cap of 48.6M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while PRPO trades at $25.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas PRPO's P/E ratio is -104.77. In terms of profitability, ENZ's ROE is -0.39%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, ENZ is more volatile compared to PRPO. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check PRPO's competition here
MDxHealth S.A. (NASDAQ: MDXH)
ENZ vs MDXH Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, MDXH has a market cap of 34.6M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while MDXH trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas MDXH's P/E ratio is -1.77. In terms of profitability, ENZ's ROE is -0.39%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, ENZ is more volatile compared to MDXH. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check MDXH's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
ENZ vs QUCY Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, QUCY has a market cap of 30.5M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while QUCY trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas QUCY's P/E ratio is -0.06. In terms of profitability, ENZ's ROE is -0.39%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, ENZ is more volatile compared to QUCY. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check QUCY's competition here
Akumin Inc. (NASDAQ: AKU)
ENZ vs AKU Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas AKU's P/E ratio is -0.13. In terms of profitability, ENZ's ROE is -0.39%, compared to AKU's ROE of -5.32%. Regarding short-term risk, ENZ is more volatile compared to AKU. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check AKU's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
ENZ vs CEMI Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas CEMI's P/E ratio is -0.63. In terms of profitability, ENZ's ROE is -0.39%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, ENZ is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check CEMI's competition here
Psychemedics Corporation (NASDAQ: PMD)
ENZ vs PMD Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas PMD's P/E ratio is -5.24. In terms of profitability, ENZ's ROE is -0.39%, compared to PMD's ROE of -0.32%. Regarding short-term risk, ENZ is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
ENZ vs ME Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas ME's P/E ratio is -0.03. In terms of profitability, ENZ's ROE is -0.39%, compared to ME's ROE of -42.03%. Regarding short-term risk, ENZ is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
ENZ vs MYNZ Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, ENZ's ROE is -0.39%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, ENZ is more volatile compared to MYNZ. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check MYNZ's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
ENZ vs BNR Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, BNR has a market cap of 12.2M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while BNR trades at $13.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas BNR's P/E ratio is -13.29. In terms of profitability, ENZ's ROE is -0.39%, compared to BNR's ROE of -0.13%. Regarding short-term risk, ENZ is more volatile compared to BNR. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check BNR's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
ENZ vs ADVB Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, ADVB has a market cap of 11.2M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while ADVB trades at $8.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas ADVB's P/E ratio is -73.45. In terms of profitability, ENZ's ROE is -0.39%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, ENZ is more volatile compared to ADVB. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check ADVB's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
ENZ vs CHEK Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas CHEK's P/E ratio is -0.43. In terms of profitability, ENZ's ROE is -0.39%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, ENZ is more volatile compared to CHEK. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
ENZ vs CNTG Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas CNTG's P/E ratio is -0.23. In terms of profitability, ENZ's ROE is -0.39%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, ENZ is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check CNTG's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
ENZ vs NDRA Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, NDRA has a market cap of 7.3M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while NDRA trades at $5.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas NDRA's P/E ratio is -0.73. In terms of profitability, ENZ's ROE is -0.39%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, ENZ is more volatile compared to NDRA. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
ENZ vs APDN Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas APDN's P/E ratio is -0.10. In terms of profitability, ENZ's ROE is -0.39%, compared to APDN's ROE of -7.23%. Regarding short-term risk, ENZ is more volatile compared to APDN. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
ENZ vs NVTA Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas NVTA's P/E ratio is -0.00. In terms of profitability, ENZ's ROE is -0.39%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, ENZ is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for ENZ.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDX)
ENZ vs LMDX Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas LMDX's P/E ratio is -0.01. In terms of profitability, ENZ's ROE is -0.39%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, ENZ is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for ENZ.Check LMDX's competition here
LumiraDx Limited (NASDAQ: LMDXW)
ENZ vs LMDXW Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, ENZ's ROE is -0.39%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, ENZ is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for ENZ.Check LMDXW's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
ENZ vs BIAFW Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, BIAFW has a market cap of 4.6M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while BIAFW trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas BIAFW's P/E ratio is 0.49. In terms of profitability, ENZ's ROE is -0.39%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, ENZ is more volatile compared to BIAFW. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check BIAFW's competition here
DermTech, Inc. (NASDAQ: DMTK)
ENZ vs DMTK Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas DMTK's P/E ratio is -0.04. In terms of profitability, ENZ's ROE is -0.39%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, ENZ is more volatile compared to DMTK. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
ENZ vs NOTV Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas NOTV's P/E ratio is -0.03. In terms of profitability, ENZ's ROE is -0.39%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, ENZ is more volatile compared to NOTV. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check NOTV's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
ENZ vs BIAF Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, BIAF has a market cap of 2.6M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while BIAF trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas BIAF's P/E ratio is -0.73. In terms of profitability, ENZ's ROE is -0.39%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, ENZ is more volatile compared to BIAF. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check BIAF's competition here
SeqLL Inc. (NASDAQ: SQL)
ENZ vs SQL Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas SQL's P/E ratio is -0.40. In terms of profitability, ENZ's ROE is -0.39%, compared to SQL's ROE of -30.46%. Regarding short-term risk, ENZ is more volatile compared to SQL. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
ENZ vs AWH Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas AWH's P/E ratio is -0.09. In terms of profitability, ENZ's ROE is -0.39%, compared to AWH's ROE of +1.62%. Regarding short-term risk, ENZ is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
ENZ vs HTGM Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas HTGM's P/E ratio is -0.03. In terms of profitability, ENZ's ROE is -0.39%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, ENZ is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
ENZ vs BIOC Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas BIOC's P/E ratio is -0.01. In terms of profitability, ENZ's ROE is -0.39%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, ENZ is more volatile compared to BIOC. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check BIOC's competition here
iSpecimen Inc. (NASDAQ: ISPC)
ENZ vs ISPC Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, ISPC has a market cap of 184.7K. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while ISPC trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas ISPC's P/E ratio is -0.04. In terms of profitability, ENZ's ROE is -0.39%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, ENZ is more volatile compared to ISPC. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check ISPC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
ENZ vs SQLLW Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, ENZ's ROE is -0.39%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, ENZ is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for ENZ.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
ENZ vs WGSWW Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, ENZ's ROE is -0.39%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, ENZ is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check WGSWW's competition here
Danaher Corporation (NYSE: DHR-PA)
ENZ vs DHR-PA Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, ENZ's ROE is -0.39%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, ENZ is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check DHR-PA's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
ENZ vs PRXL Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas PRXL's P/E ratio is 42.97. In terms of profitability, ENZ's ROE is -0.39%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, ENZ is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check PRXL's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
ENZ vs BNGOW Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas BNGOW's P/E ratio is N/A. In terms of profitability, ENZ's ROE is -0.39%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, ENZ is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for ENZ.Check BNGOW's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
ENZ vs NDRAW Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas NDRAW's P/E ratio is N/A. In terms of profitability, ENZ's ROE is -0.39%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, ENZ is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for ENZ.Check NDRAW's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
ENZ vs MEUSW Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas MEUSW's P/E ratio is N/A. In terms of profitability, ENZ's ROE is -0.39%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, ENZ is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for ENZ.Check MEUSW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
ENZ vs CHEKZ Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, ENZ's ROE is -0.39%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, ENZ is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for ENZ.Check CHEKZ's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
ENZ vs OCDX Comparison September 2026
Enzo Biochem, Inc. (NYSE: ENZ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENZ stands at 16.4M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, ENZ is priced at $0.31 on the NYSE, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENZ currently has a P/E ratio of -2.24, whereas OCDX's P/E ratio is -42.28. In terms of profitability, ENZ's ROE is -0.39%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, ENZ is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for ENZ.Check OCDX's competition here